Tag: GlobalData
Next-generation sequencing breakthroughs drive personalized medicine into mainstream healthcare, says GlobalData
This evolution holds the promise of tailoring medical interventions to individual genetic profiles for more effective and targeted healthcare outcomes, according to GlobalData, a leading data and analytics company
GLP1R-targeting drugs dominate type 2 diabetes pipeline, reveals GlobalData
This indicates a shift from the conventional IR to the GLP1R as the primary target for pioneering T2D treatments, says GlobalData, a leading data and analytics company
Deep tech startups catalysts for innovation & industrial transformation, says GlobalData
GlobalData’s latest Startup Series report, “Deep tech alchemy: how innovators disrupt industry,” explores 12 emerging deep tech domains and their sub-domains, revealing insights into startup-driven transformations
India’s mycobacterium tuberculosis tests market to grow at 4% CAGR through...
With a staggering 2.64 million reported cases in 2022, tuberculosis remains a formidable public health challenge
Inflation law drives biologic drugs to outpace small molecules in venture...
According to GlobalData’s Pharma Intelligence Center Deals database, the US biotechs saw 48% or $1.1 billion more in innovator drug venture financing, reaching a total deal value of $3.2 billion in 2023
Inflammatory bowel disease treatments reach inflection point requiring active comparators, says...
The current situation would be best addressed through clinical asset evaluation through trials with active comparators
Alnylam patent lawsuit against Pfizer, Moderna highlights escalating legal pressure on...
The potential for lucrative settlements in the multi-billion-dollar COVID-19 vaccine market adds further significance to these legal battles
Ultragenyx’s UX053 Phase I/II study termination a minor setback for mRNA...
The study was terminated due to reasons unrelated to safety concerns, although the specific rationale has not been disclosed by the biopharmaceutical company
US biotech IPO market yet to see previous high levels due...
According to GlobalData’s Pharma Intelligence Center Deals database, there were over 300 completed IPOs from 2018 to 2022 in the US.
Chinese regulators focus on homegrown COVID-19 therapies to tackle new variants,...
According to GlobalData’s Pharma Intelligence Center, there are currently 16 COVID-19 drugs in clinical development in China, five of which are in Phase III